Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 27, 2022 at 10:38 am EDT
Share
Hangzhou Biotest Biotech Co.,Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 1,017.27 million compared to CNY 491.83 million a year ago. Revenue was CNY 1,017.27 million compared to CNY 491.83 million a year ago. Net income was CNY 492.53 million compared to CNY 233.15 million a year ago. Basic earnings per share from continuing operations was CNY 4.62 compared to CNY 2.91 a year ago. Diluted earnings per share from continuing operations was CNY 4.62 compared to CNY 2.91 a year ago.
Hangzhou Biotest Biotech Co Ltd is a company mainly engaged in the research and development (R&D), production and sales of point-of-care testing (POCT) diagnostic reagents. The Company's products include reproductive health testing series, such as human chorionic gonadotropin testing reagent and luteinizing hormone testing reagent, and drug abuse testing series, such as morphine testing reagent and cocaine testing reagent, and infectious disease testing series, such as adenovirus testing reagent and typhoid antibody testing reagent, and tumor marker testing series, such as alpha fetoprotein detection reagent, and myocardial marker detection series, such as dimer detection reagent and myocardial series detection reagent.